Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
June 18, 2024 16:30 ET | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET | Tenaya Therapeutics, Inc.
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
May 02, 2024 17:00 ET | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:30 ET | Tenaya Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Tenaya_Logo_FullColor-RGB.jpg
Tenaya Therapeutics to Present Data for TN-301 and TN-201 at Upcoming Medical Conferences
September 21, 2023 16:05 ET | Tenaya Therapeutics, Inc.
TN-301 First-in-Human Phase 1 Clinical Trial Results and Preclinical Combination Data to be Presented at Heart Failure Society of America Annual Scientific Meeting TN-201 Interim Seroprevalence Study...
Imbria_Logo_Colour.png
Imbria Pharmaceuticals Completes Enrollment in the Phase 2 IMPROVE-ISCHEMIA Clinical Trial of Ninerafaxstat in Patients with Stable Angina
August 16, 2023 08:00 ET | Imbria Pharmaceuticals Inc.
– IMPROVE-ISCHEMIA, a randomized, placebo-controlled trial, with topline data expected in 4Q 2023 – – Additional Phase 2 data read-outs expected in 4Q 2023, including topline from the IMPROVE-HCM...
22157.jpg
Worldwide Precision Cardiology Industry to 2027 - by Offering, Sample Type, Technology, Application, End-user and Region
October 26, 2022 07:48 ET | Research and Markets
Dublin, Oct. 26, 2022 (GLOBE NEWSWIRE) -- The "Global Precision Cardiology Market: Competition Forecast and Opportunities to 2027" report has been added to ResearchAndMarkets.com's offering.The...
Global Precision Cardiology Market
Global Precision Cardiology Industry 2021-2031: Focus on Offering, Sample, Technology, Application, End-user, and Region
February 28, 2022 06:28 ET | Research and Markets
Dublin, Feb. 28, 2022 (GLOBE NEWSWIRE) -- The "Precision Cardiology Market - A Global and Regional Analysis: Focus on Offering, Sample, Technology, Application, End User, and Region - Analysis and...
Healthtech Solutions, Inc. (HLTT), Parent Company of Cutting-Edge Medical Technology Companies, Files Reg A With SEC
March 17, 2021 08:30 ET | Healthtech Solutions, Inc.
March 8, 2021, filing to raise up to $75 million.  Maximum of 1,500,000 shares of Series B preferred stock offered at price of $50 per share.Healthtech Solutions, Inc. is organized to pursue...
Reports and Data.jpeg-01
Cardiomyopathy Medication Market To Reach USD 1,148.9 Million By 2026 | Reports And Data
November 04, 2019 12:11 ET | Reports and Data
New York, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Rising prevalence of cardiomyopathy diseases, new product development for targeted cardiac illnesses, collaborations for medical advancements and...